Clearmind Medicine (NASDAQ:CMND) Posts Quarterly Earnings Results

Posted by Stanley Muller on Jun 15th, 2026

Clearmind Medicine (NASDAQ:CMND – Get Free Report) announced its earnings results on Monday. The company reported ($6.78) EPS for the quarter, Zacks reports.

Clearmind Medicine Stock Performance

Shares of CMND stock traded up $0.03 during trading on Monday, hitting $3.37. 102,555 shares of the company were exchanged, compared to its average volume of 1,144,939. The firm has a market capitalization of $3.43 million, a price-to-earnings ratio of -0.02 and a beta of 0.64. The business’s 50-day simple moving average is $6.22 and its 200 day simple moving average is $16.48. Clearmind Medicine has a twelve month low of $2.10 and a twelve month high of $524.00.

Insider Activity at Clearmind Medicine

In related news, major shareholder Financial Lp Hrt sold 225,191 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $0.12, for a total transaction of $27,022.92. Following the completion of the sale, the insider directly owned 1,838,075 shares in the company, valued at approximately $220,569. This trade represents a 10.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded shares of Clearmind Medicine to a “sell” rating in a report on Saturday, May 23rd.

Read Our Latest Stock Report on CMND

Clearmind Medicine Company Profile

(Get Free Report)

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.